Overview

Nonalcoholic Steatohepatitis (NASH) Market is forecasted to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

FutureWise Market Research has illustrated a report on the Nonalcoholic Steatohepatitis (NASH) Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Nonalcoholic Steatohepatitis (NASH) Market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Nonalcoholic Steatohepatitis (NASH) Market are:    
• Boehringer Ingelheim
• Cerenis Therapeutics
• Connexios Life Sciences
• Genfit
• Islet Sciences
• Nimbus Therapeutics
• Verva Pharmaceuticals
• Viking Therapeutics
• Astazeneca Plc
• Novo Nordisk
(Note: The list of the major players will be updated with the latest market scenario and trends)

Nonalcoholic Steatohepatitis (NASH) Market Segmentation:
By Product Type
• Weight Loss Treatment
• Insulin-Sensitizing Agents
• Lipid-Lowering Drugs
• Antioxidants
• Others
By Application
• Hospital
• Clinic
• Research Institute
• Others
By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the market by product type, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industryspecific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
      1 Introduction 
          1.1 Objectives of the Study 
          1.2 Market Definition 
          1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
          1.4 Currency 
          1.5 Limitations 
          1.6 Stakeholders 
 2.  Research Methodology 
      2.1 Research Data 
         2.1.1 Secondary Data
                 2.1.1.1 Key Data From Secondary Sources
         2.1.2 Primary Data
                 2.1.2.1 Key Data From Primary Sources
      2.2 Market Size Estimation 
      2.3 Market Breakdown and Data Triangulation 
      2.4 Assumptions for the Study  
3. Executive Summary
        3.1 Market Outlook
        3.2 Segment Outlook
        3.3 Competitive Insights
4. Global  Nonalcoholic Steatohepatitis (NASH) Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards And Compliances
5. Market Overview
     5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global  Nonalcoholic Steatohepatitis (NASH) Market Analysis Tools
         6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies
7. Global  Nonalcoholic Steatohepatitis (NASH) Market, By Product Type Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. Weight Loss Treatment
           7.2. Insulin-Sensitizing Agents
           7.3. Lipid-Lowering Drugs
           7.4. Antioxidants
           7.5. Others
8. Global  Nonalcoholic Steatohepatitis (NASH) Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Hospital
           8.2. Clinic
           8.3. Research Institute
           8.4. Others
9.  North America  Nonalcoholic Steatohepatitis (NASH) Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
     9.1. Introduction
     9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            9.2.1. U.S.A
            9.2.2. Canada
     9.3. Market Size (USD Million) Forecast for North America 2020-2027
10. Europe  Nonalcoholic Steatohepatitis (NASH) Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
     10.1. Introduction
     10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.2.1. Germany
            10.2.2. U.K
           10.2.3. France
           10.2.4. Italy
           10.2.5. Spain
           10.2.6. Russia
           10.2.7. Poland
           10.2.8. Switzerland
           10.2.9.Rest of Western Europe
11. Asia Pacific  Nonalcoholic Steatohepatitis (NASH) Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along
       with expected regulatory needs
        11.1. Introduction
        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             11.2.1. Japan
             11.2.2. China
             11.2.3. Singapore
             11.2.4. India
             11.2.5. Australia and New Zealand
             11.2.6. ASEAN
             11.2.7. South Korea
             11.2.8. Rest of Asia Pacific
        11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
  12. Rest of the World  Nonalcoholic Steatohepatitis (NASH) Market Analysis 2015–2019 and Forecast
         2020–2027 (USD Million) along with expected regulatory needs
        12.1. Introduction
        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             12.2.1. Saudi Arabia
             12.2.2. UAE
             12.2.3. South Africa
             12.2.4. Egypt
        12.3. Market Size (USD Million) Forecast for MEA 2020-2027
           
    13. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
         13.1. Boehringer Ingelheim
                13.1.1. Company Overview
                13.1.2. Product Portfolio
                13.1.3. SWOT Analysis
                13.1.4. Financial Overview
                13.1.5. Strategic Overview
         13.2. Cerenis Therapeutics
                13.2.1. Company Overview
                13.2.2. Product Portfolio
                13.2.3. SWOT Analysis
                13.2.4. Financial Overview
                13.2.5. Strategic Overview
         13.3. Connexios Life Sciences
                13.3.1. Company Overview
                13.3.2. Product Portfolio
                13.3.3. SWOT Analysis
                13.3.4. Financial Overview
                13.3.5. Strategic Overview
         13.4. Genfit
                13.4.1. Company Overview
                13.4.2. Product Portfolio
                13.4.3. SWOT Analysis
                13.4.4. Financial Overview
                13.4.5. Strategic Overview
         13.5. Islet Sciences 
                13.5.1. Company Overview
                13.5.2. Product Portfolio
                13.5.3. SWOT Analysis
                13.5.4. Financial Overview
                13.5.5. Strategic Overview
         13.6. Nimbus Therapeutics
                13.6.1. Company Overview
                13.6.2. Product Portfolio
                13.6.3.  SWOT Analysis
                13.6.4. Financial Overview
                13.6.5. Strategic Overview
         13.7. Verva Pharmaceuticals
                13.7.1. Company Overview
                13.7.2. Product Portfolio
                13.7.3. SWOT Analysis
                13.7.4. Financial Overview
                13.7.5. Strategic Overview
         13.8. Viking Therapeutics
                13.8.1. Company Overview
                13.8.2. Product Portfolio
                13.8.3. SWOT Analysis
                13.8.4. Financial Overview
                13.8.5. Strategic Overview
         13.9. Astazeneca Plc
                13.9.1. Company Overview
                13.9.2. Product Portfolio
                13.9.3. SWOT Analysis
                13.9.4. Financial Overview
                13.9.5. Strategic Overview
         13.10. Novo Nordisk
                13.10.1. Company Overview
                13.10.2. Product Portfolio
                13.10.3.  SWOT Analysis
                13.10.4. Financial Overview
                13.10.5. Strategic Overview
14. FutureWise SME key takeaway points for Client

Tables

Figures